Novel  fusion oncogene in congenital acute myeloid leukemia and implications for menin inhibitor therapy.

Rebecca Voss; Wenqing Qi; La'Ron Browne; Ruth W. Wang’ondu; Mahsa Khanlari; Jing Ma; X X; Josi Lott; Juan M. Barajas; Melvin Thomas III; Victor B. Pastor Loyola; Hui Cao; Larissa V. Furtado; Swati Naik; Sakshi Bami; Seth E. Karol; Jeffrey E. Rubnitz; Jeffery M. Klco; Yen-Chun Liu; L Wang

doi:10.3324/haematol.2025.300350

← 뒤로

Novel fusion oncogene in congenital acute myeloid leukemia and implications for menin inhibitor therapy.

2/5 보강

Haematologica 2026 OA Acute Myeloid Leukemia Research

OpenAlex 토픽 · Acute Myeloid Leukemia Research Protein Degradation and Inhibitors Microtubule and mitosis dynamics

Voss RK, Qi W, Browne L, Wang'ondu RW, Khanlari M, Ma J, Ma X, Lott J, Barajas JM, Thomas Iii M, Loyola VBP, Cao H, Furtado LV, Naik S, Bami S, Karol SE, Rubnitz JE, Klco JM, Liu YC, Wang L

🔓 OA 전문 ↗ 원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

📝 환자 설명용 한 줄

Not available.

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Rebecca Voss, Wenqing Qi, et al. (2026). Novel fusion oncogene in congenital acute myeloid leukemia and implications for menin inhibitor therapy.. Haematologica. https://doi.org/10.3324/haematol.2025.300350

MLA Rebecca Voss, et al.. "Novel fusion oncogene in congenital acute myeloid leukemia and implications for menin inhibitor therapy.." Haematologica, 2026.

PMID 42021697

DOI 10.3324/haematol.2025.300350

Abstract

Not available.

같은 제1저자의 인용 많은 논문 (1)

Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.
Leukemia 2025